Quidel Co. (NASDAQ:QDEL) has earned an average recommendation of “Buy” from the eleven research firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and three have issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $68.00.
Several research analysts have issued reports on QDEL shares. TheStreet upgraded Quidel from a “c+” rating to a “b” rating in a report on Wednesday, November 7th. Canaccord Genuity lowered Quidel to a “buy” rating in a report on Tuesday, December 11th. Zacks Investment Research upgraded Quidel from a “hold” rating to a “buy” rating and set a $75.00 price target on the stock in a report on Thursday, November 8th. BidaskClub upgraded Quidel from a “hold” rating to a “buy” rating in a report on Friday, October 12th. Finally, ValuEngine upgraded Quidel from a “hold” rating to a “buy” rating in a report on Friday.
In other news, CFO Randall J. Steward sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $61.51, for a total value of $922,650.00. Following the transaction, the chief financial officer now owns 16,790 shares in the company, valued at $1,032,752.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Douglas C. Bryant sold 25,250 shares of the firm’s stock in a transaction that occurred on Tuesday, January 29th. The shares were sold at an average price of $55.09, for a total value of $1,391,022.50. Following the completion of the transaction, the chief executive officer now owns 319,563 shares in the company, valued at approximately $17,604,725.67. The disclosure for this sale can be found here. Insiders sold 58,283 shares of company stock worth $3,416,751 in the last 90 days. Corporate insiders own 16.70% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Northern Trust Corp increased its position in shares of Quidel by 15.4% during the second quarter. Northern Trust Corp now owns 423,108 shares of the company’s stock valued at $28,136,000 after acquiring an additional 56,538 shares during the last quarter. United Services Automobile Association increased its position in shares of Quidel by 26.4% during the second quarter. United Services Automobile Association now owns 7,382 shares of the company’s stock valued at $491,000 after acquiring an additional 1,542 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of Quidel during the third quarter valued at approximately $689,000. Vanguard Group Inc. increased its position in shares of Quidel by 5.5% during the third quarter. Vanguard Group Inc. now owns 2,929,387 shares of the company’s stock valued at $190,909,000 after acquiring an additional 152,702 shares during the last quarter. Finally, Rothschild & Co. Asset Management US Inc. increased its position in Quidel by 17.5% in the third quarter. Rothschild & Co. Asset Management US Inc. now owns 449,622 shares of the company’s stock worth $29,302,000 after buying an additional 67,057 shares during the last quarter. Institutional investors own 90.83% of the company’s stock.
NASDAQ:QDEL traded up $1.83 on Friday, hitting $58.37. The stock had a trading volume of 250,110 shares, compared to its average volume of 278,074. The firm has a market cap of $2.30 billion, a P/E ratio of -833.86, a PEG ratio of 0.84 and a beta of 1.27. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.86 and a current ratio of 1.26. Quidel has a 52 week low of $41.50 and a 52 week high of $77.63.
Quidel (NASDAQ:QDEL) last announced its quarterly earnings results on Tuesday, November 6th. The company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.16. The business had revenue of $117.40 million for the quarter, compared to analyst estimates of $120.09 million. Quidel had a return on equity of 25.63% and a net margin of 7.26%. The company’s quarterly revenue was up 130.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.17 earnings per share. On average, equities analysts forecast that Quidel will post 2.61 earnings per share for the current fiscal year.
Quidel Company Profile
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
Read More: Why is the conference call important?
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.